Luisa Fofi

fofi


Dott.ssa Luisa Fofi

  • Laurea in Medicina e Chirurgia con lode, discutendo una tesi dal titolo: “La stimolazione magnetica ripetitiva delle aree motorie cerebrali nei soggetti normali e nei pazienti con disturbi del movimento”, relatore Prof. Mario Manfredi, correlatore Prof. Alfredo Berardelli (20/07/2000)
  • Abilitazione professionale di Medico-Chirurgo ed iscrizione all’Ordine dei Medici Chirurghi della provincia di Roma con numero M51172 (09/10/2001)
  • Diploma di Specializzazione in Neurologia con lode, discutendo una tesi dal titolo: “Ricerca di polimorfismi genici in una serie non selezionata di pazienti affetti da patologia cerebrovascolare”, relatore: Prof. M. Prencipe, correlatore Prof. D. Toni) (14/11/2005)
  • Diploma di Master di Malattie Cerebrovascolari presso l’Università di Roma “La Sapienza” (27/01/2009)
  • 2005-2007 ha lavorato come Neurologo presso il Reparto di Riabilitazione Neuromotoria dell’IRCCS San Raffaele Pisana e nel 2007-2008 presso il Reparto di Riabilitazione Neuromotoria dell’IRCCS San Raffaele Nomentano.
  • IX Corso di Perfezionamento in Diagnosi e Terapia delle Cefalee (2009/2010)
  • Membro del consiglio direttivo dell’AIC – Associazione Italiana per la Lotta contro le Cefalee- Onlus.
  • Scuola quadriennale di Perfezionamento in Agopuntura e Tecniche Complementari A.M.I.A.R – C.S.T.N.F. – Centro Studi Terapie Naturali e Fisiche di Torino, per un totale di 480 ore di insegnamento teorico-pratico (2010-2014)
  • Diploma in “Clinical Practice in Acupuncture” presso il ‘Chine Nanjing International Acupuncture Training Centre’ dell’Università di Medicina Tradizionale Cinese di Nanchino in Cina (19/08/2014-04/09/2014)
  • Attestato Italiano di Agopuntura FISA, presso la scuola CSTNF di Torino discutendo la tesi dal titolo “L’agopuntura nella cefalea a grappolo-6 casi clinici e revisione della letteratura” con votazione: 30/30 e lode. (15/11/2014)
  • Dal 2007 continua a svolgere regolarmente attività di ricerca e attività ambulatoriale neurologica presso l’IRCCS San Raffaele Pisana a Roma, in particolare nel Centro Cefalee (Responsabile: Dott. Piero Barbanti) ed in altri studi privatamente.
  • Nelle stesse sedi svolge inoltre attività di agopuntura.

Lavori pubblicati su riviste scientifiche internazionali:

  • Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine.
  • Barbanti P, Egeo G, Fofi L, Aurilia C, Piroso S. Neurol Sci. 2015 May;36 Suppl 1:29-32
  • Look beyond Catechol-O-Methyltransferase genotype for cathecolamines derangement in migraine: the BioBIM rs4818 and rs4680 polymorphisms study. De Marchis ML, Barbanti P, Palmirotta R, Egeo G, Aurilia C, Fofi L, Piroso S, Ialongo C, Della-Morte D, D’Andrea G, Ferroni P, Guadagni F. J Headache Pain. 2015 Dec;16(1):520.
  • Progesterone Receptor Gene (PROGINS) Polymorphism Correlates with Late Onset of Migraine.
  • Palmirotta R, Barbanti P, Ialongo C, De Marchis ML, Alessandroni J, Egeo G, Aurilia C, Fofi L, Valente MG, Ferroni P, Della-Morte D, Guadagni F. DNA Cell Biol. 2014 Dec 10.
  • Is SOD2 Ala16Val Polymorphism Associated with Migraine with Aura Phenotype?
  • Palmirotta R, Barbanti P, De Marchis ML, Egeo G, Aurilia C, Fofi L, Ialongo C, Valente MG, Ferroni P, Della-Morte D, Guadagni F. Antioxid Redox Signal. 2014 Nov 11.
  • Acupuncture in cluster headache: four cases and review of the literature.
  • Fofi L, Allais G, Quirico PE, Rolando S, Borgogno P, Barbanti P, Benedetto C.
  • Neurol Sci. 2014 May;35 Suppl 1:195-8. doi: 10.1007/s10072-014-1769-6.
  • Treatment of tension-type headache: from old myths to modern concepts.
  • Barbanti P, Egeo G, Aurilia C, Fofi L. Neurol Sci. 2014 May;35 Suppl 1:17-21.
  • Drugs targeting nitric oxide synthase for migraine treatment. Barbanti P, Egeo G, Aurilia C, Fofi L, Della-Morte D. Expert Opin Investig Drugs. 2014 May 12:1-8.
  • Headache in chronic cocaine users: A cross-sectional study. Fofi L, Orlandi V, Vanacore N, Mizzoni MC, Rosa A, Aurilia C, Egeo G, Casella P, Barbanti P. Cephalalgia. 2014 Feb 5.
  • Association between migraine and ACE gene (insertion/deletion) polymorphism: the BioBIM study. Palmirotta R, Barbanti P, Ludovici G, De Marchis ML, Ialongo C, Egeo G, Aurilia C, Fofi L, Abete P, Spila A, Ferroni P, Della-Morte D, Guadagni F. Pharmacogenomics. 2014 Feb;15(2):147-55.
  • Dopaminergic symptoms in migraine. Barbanti P, Fofi L, Aurilia C, Egeo G.
  • Neurol Sci. 2013 May;34 Suppl 1:S67-70.
  • Prion protein gene M129V polymorphism and variability in age at migraine onset. Palmirotta R, Ludovici G, Egeo G, Ialongo C, Aurilia C, Fofi L, De Marchis ML, Della-Morte D, Barbanti P, Guadagni F. Headache. 2013 Mar;53(3):540-5.
  • Establishment of a biorepository for migraine research: the experience of Interinstitutional Multidisciplinary BioBank (BioBIM). Palmirotta R, Barbanti P, Ludovici G, Egeo G, Aurilia C, Fofi L, De Marchis ML, Spila A, Ferroni P, Della-Morte D, Guadagni F. Neurol Sci. 2013 Sep;34(9):1659-63.
  • A case-control study on excessive daytime sleepiness in chronic migraine. Barbanti P, Aurilia C, Egeo G, Fofi L, Vanacore N. Sleep Med. 2013 Mar;14(3):278-81.
  • Future trends in drugs for migraine prophylaxis. Barbanti P, Aurilia C, Egeo G, Fofi L. Neurol Sci. 2012 May;33 Suppl 1:S137-40.
  • Cerebral transverse sinus morphology as detected by MR venography in patients with chronic migraine. Fofi L, Giugni E, Vadalà R, Vanacore N, Aurilia C, Egeo G, Pierallini A, Barbanti P. Headache. 2012 Sep;52(8):1254-61.
  • Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial. Barbanti P, Fofi L, Dall’Armi V, Aurilia C, Egeo G, Vanacore N, Bonassi S.
  • J Headache Pain. 2012 Jul;13(5):407-14.
  • An observational study on electrolyte disorders in the acute phase of ischemic stroke and their prognostic value. Fofi L, Dall’armi V, Durastanti L, Valenza A, Lorenzano S, Prencipe M, Toni D. J Clin Neurosci. 2012 Apr;19(4):513-6.
  • Systemic thrombolysis in patients with acute ischemic stroke and Internal Carotid ARtery Occlusion: the ICARO study. Paciaroni M, Balucani C, Agnelli G, Caso V, Silvestrelli G, Grotta JC, Demchuk AM, Sohn SI, Orlandi G, Leys D, Pezzini A, Alexandrov AV, Silvestrini M, Fofi L, Barlinn K, Inzitari D, Ferrarese C, Tassi R, Tsivgoulis G, Consoli D, Baldi A, Bovi P, Luda E, Galletti G, Invernizzi P, DeLodovici ML, Corea F, Del Sette M, Monaco S, Marcheselli S, Alberti A, Venti M, Acciarresi M, D’Amore C, Macellari F, Lanari A, Previdi P, Gonzales NR, Pandurengan RK, Vahidy FS, Sline M, Bal SS, Chiti A, Gialdini G, Dumont F, Cordonnier C, Debette S, Padovani A, Cerqua R, Bodechtel U, Kepplinger J, Nesi M, Nencini P, Beretta S, Trentini C, Martini G, Piperidou C, Heliopoulos I, D’Anna S, Cappellari M, Donati E, Bono G, Traverso E, Toni D. Stroke. 2012 Jan;43(1):125-30.
  • Restless legs syndrome is not associated with migraine with aura: a clinical study.
  • D’Onofrio F, Cologno D, Petretta V, Finocchi C, Autunno M, Marsala G, Usai S, Grazzi L, Omboni S, Fofi L, Barbanti P, Bussone G. Neurol Sci. 2011 May;32 Suppl 1:S153-6.
  • Migraine prophylaxis: what is new and what we need? Barbanti P, Aurilia C, Egeo G, Fofi L. Neurol Sci. 2011 May;32 Suppl 1:S111-5.
  • Hypertension as a risk factor for migraine chronification. Barbanti P, Aurilia C, Egeo G, Fofi L. Neurol Sci. 2010 Jun;31 Suppl 1:S41-3.
  • The COX-2 G/C -765 polymorphism may modulate the occurrence of cerebrovascular ischemia. Colaizzo D, Fofi L, Tiscia G, Guglielmi R, Cocomazzi N, Prencipe M, Margaglione M, Toni D. Blood Coagul Fibrinolysis. 2006 Mar;17(2):93-6.
  • Depressed intracortical inhibition after long trains of subthreshold repetitive magnetic stimuli at low frequency. Modugno N, Currà A, Conte A, Inghilleri M, Fofi L, Agostino R, Manfredi M, Berardelli A. Clin Neurophysiol. 2003 Dec;114(12):2416-22.
  • Spread of electrical activity at cortical level after repetitive magnetic stimulation in normal subjects. Lorenzano C, Gilio F, Inghilleri M, Conte A, Fofi L, Manfredi M, Berardelli A. Exp Brain Res. 2002 Nov;147(2):186-92.

Protocolli clinici sponsorizzati (GCP-ICH):

  • MS-LAQ-302 BRAVO STUDY (TEVA). A  Multinational , multicenter, randomized, parallel-group study performed in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of interferon B-1 a (Avonex) in a rater-blinded design.
  • CL3-18886-012 THE PERFORM STUDY (SERVIER). An international, randomised, double-blind, two parallel group comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration. Enrolling is completed.
  • BI 1246.4 STUDY (BOERINGHER INGELHEIM). A  Multinational, multicenter, randomized, parallel-group study comparing placebo vs BI 44370 TA (50 mg, 200 mg, 400 mg) administered orally during a migraine attack of moderate-severe intensity. Enrolling is completed.
  • MK 3207-005 STUDY (MERCK SHARP & DOHME). A Multinational, multicenter, randomized, Double-Blind, placebo-controlled trial for the Treatment of Acute Migraine Attack.
  • MK 0462-085 STUDY (MERCK SHARP & DOHME). A multicenter, randomized, double-blind, placebo-controlled crossover trial to evaluate the Efficacy and Tolerability of Rizatriptan 10 mg ODT for the treatment of acute migraine in patients on topiramate for migraine prophilaxis.
  • MK 0462-088 (MERCK SHARP & DOHME). A double-blind, placebo controlled, parallel group study to compare the efficacy of rizatriptan 10 mg lyophilized wafer in the acute treatment of migraine in patients with unilateral trigeminal autonomic symptoms.
  • Lumi/09/Fro+Dex-Mig/001 (INNOPHARMACO, Istituto Lusopharmaco d’Italia S.p.A). Comparison between frovatriptan plus different treatment regimens of dexketoprofen (25 mg and 37.5 mg) and frovatriptan alone in the acute treatment of migraine without aura and migraine with aura attacks.
  • MK 0462-082 STUDY (MERCK SHARP & DOHME). Studio clinico internazionale, randomizzato, in doppio cieco, controllato verso placebo e a gruppi paralleli, per valutare la sicurezza e l’efficacia di Rizatriptan per il trattamento dell’emicrania in fase acuta in bambini ed adolescenti.
  • Protocollo 110390 (GLAXOSMITHKLINE BIOLOGICALS): A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals’ gE/AS01B vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 50 years and older.
  • Protocollo 113077(GLAXOSMITHKLINE BIOLOGICALS): A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety and immunogenicity of GSK Biologicals’ gE/AS01B vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 70 years and older.